{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T08:54:34Z","timestamp":1793350474019,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100030841","name":"Exact Sciences Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030841","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.annonc.2026.04.007","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T23:53:19Z","timestamp":1776383599000},"page":"920-935","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+\/HER2\u2212 and ADAPTcycle trials (N = 7914)"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6019-7544","authenticated-orcid":false,"given":"O.","family":"Gluz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Nitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Christgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kuemmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Thill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Wuerstlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Aktas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"L\u00fcdtke-Heckenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Zaiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Bjelic-Radisic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Just","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Veselinovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Baehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Wujak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Warm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Schumacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Schem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Forstbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Krauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Graeser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hartkopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Kates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"zu Eulenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9614-6586","authenticated-orcid":false,"given":"K.","family":"J\u00f3\u017awiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8201-9294","authenticated-orcid":false,"given":"S.","family":"Burmeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.H.","family":"Kreipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9744-7372","authenticated-orcid":false,"given":"N.","family":"Harbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.annonc.2026.04.007_bib1","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.3390\/cancers14143469","article-title":"From immunohistochemistry to new digital ecosystems: a state-of-the-art biomarker review for precision breast cancer medicine","volume":"14","author":"Hacking","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.annonc.2026.04.007_bib2","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.3390\/genes14071364","article-title":"Biomarkers in breast cancer: an old story with a new end","volume":"14","author":"Neves Rebello Alves","year":"2023","journal-title":"Genes (Basel)"},{"issue":"25","key":"10.1016\/j.annonc.2026.04.007_bib3","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-Gene assay to inform chemotherapy benefit in node-positive breast cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.annonc.2026.04.007_bib4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.annonc.2026.04.007_bib5","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S1470-2045(21)00007-3","article-title":"70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age","volume":"22","author":"Piccart","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2026.04.007_bib6","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJMoa1412379","article-title":"Adjuvant ovarian suppression in premenopausal breast cancer","volume":"372","author":"Francis","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.annonc.2026.04.007_bib7","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1200\/JCO.22.01065","article-title":"Adjuvant endocrine therapy in premenopausal breast cancer: 12-year results from SOFT","volume":"41","author":"Francis","year":"2023","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.annonc.2026.04.007_bib8","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1200\/JCO.2002.05.042","article-title":"Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association Study","volume":"20","author":"Jonat","year":"2002","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.annonc.2026.04.007_bib9","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1056\/NEJMoa0909638","article-title":"Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer","volume":"362","author":"Swain","year":"2010","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.annonc.2026.04.007_bib10","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300267","article-title":"Clinical and genomic risk for late breast cancer recurrence and survival","volume":"3","author":"Sparano","year":"2024","journal-title":"NEJM Evid"},{"key":"10.1016\/j.annonc.2026.04.007_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113358","article-title":"Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive\/HER2-negative early breast cancer: a systematic review and meta-analysis","volume":"194","author":"Martins-Branco","year":"2023","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.annonc.2026.04.007_bib12","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S1470-2045(20)30458-7","article-title":"Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial","volume":"21","author":"Smith","year":"2020","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.annonc.2026.04.007_bib13","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1200\/JCO.21.02759","article-title":"Endocrine therapy response and 21-gene expression assay for therapy guidance in HR+\/HER2-early breast cancer","volume":"40","author":"Nitz","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.04.007_bib14","article-title":"Abstract LBO1-05: Impact of age and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Results from the multicenter ADAPTcycle trial (n=4,334)","volume":"84","author":"Gluz","year":"2024","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.annonc.2026.04.007_bib15","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.annonc.2023.04.002","article-title":"Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+\/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+\/HER2- trial","volume":"34","author":"Gluz","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.04.007_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920973130","article-title":"The run-in phase of the prospective WSG-ADAPT HR+\/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer","volume":"12","author":"Nitz","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.04.007_bib17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41379-018-0109-4","article-title":"An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer","volume":"32","author":"Rimm","year":"2019","journal-title":"Mod Pathol"},{"issue":"15_suppl","key":"10.1016\/j.annonc.2026.04.007_bib18","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.504","article-title":"Prospective WSG phase III PlanB trial: final analysis of adjuvant 4xEC\u21924x doc vs. 6x docetaxel\/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer","volume":"35","author":"Harbeck","year":"2017","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.annonc.2026.04.007_bib19","doi-asserted-by":"crossref","first-page":"8581","DOI":"10.1002\/cam4.4376","article-title":"TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer","volume":"10","author":"Grote","year":"2021","journal-title":"Cancer Med"},{"issue":"16_suppl","key":"10.1016\/j.annonc.2026.04.007_bib20","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.505","volume":"42","author":"Kalinsky","year":"2024","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.annonc.2026.04.007_bib21","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1904819","article-title":"Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer","volume":"380","author":"Sparano","year":"2019","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.annonc.2026.04.007_bib22","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","article-title":"Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer","volume":"24","author":"Paik","year":"2006","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.annonc.2026.04.007_bib23","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1056\/NEJMoa1510764","article-title":"Prospective validation of a 21-gene expression assay in breast cancer","volume":"373","author":"Sparano","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2026.04.007_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113473","article-title":"Quantitative expression of oestrogen receptor in breast cancer: clinical and molecular significance","volume":"197","author":"Makhlouf","year":"2024","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.annonc.2026.04.007_bib25","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/bjc.2013.756","article-title":"Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study","volume":"110","author":"Purdie","year":"2014","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.annonc.2026.04.007_bib26","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1007\/s12325-015-0268-3","article-title":"Quantitative gene expression by recurrence score in ER-positive breast cancer, by age","volume":"32","author":"Swain","year":"2015","journal-title":"Adv Ther"},{"issue":"3","key":"10.1016\/j.annonc.2026.04.007_bib27","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1470-2045(21)00758-0","article-title":"Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials","volume":"23","year":"2022","journal-title":"Lancet Oncol"},{"issue":"2 Pt 2","key":"10.1016\/j.annonc.2026.04.007_bib28","doi-asserted-by":"crossref","first-page":"951s","DOI":"10.1158\/1078-0432.951s.11.2","article-title":"Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival","volume":"11","author":"Dowsett","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"10.1016\/j.annonc.2026.04.007_bib29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10549-007-9701-x","article-title":"Letrozole in the neoadjuvant setting: the P024 trial","volume":"105 Suppl 1","author":"Ellis","year":"2007","journal-title":"Breast Cancer Res Treat"},{"issue":"17","key":"10.1016\/j.annonc.2026.04.007_bib30","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1200\/JCO.2010.31.6950","volume":"29","author":"Ellis","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4, Supplement","key":"10.1016\/j.annonc.2026.04.007_bib31","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.fertnstert.2008.09.077","article-title":"Aromatase inhibitors prevent the estrogen rise associated with the flare effect of gonadotropins in patients treated with GnRH agonists","volume":"91","author":"Bedaiwy","year":"2009","journal-title":"Fertil Steril"},{"issue":"2","key":"10.1016\/j.annonc.2026.04.007_bib32","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.04.007_bib33","first-page":"1","article-title":"AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2025","author":"Park-Simon","year":"2025","journal-title":"Breast Care (Basel)"},{"issue":"27","key":"10.1016\/j.annonc.2026.04.007_bib34","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Paik","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.annonc.2026.04.007_bib35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1470-2045(09)70314-6","article-title":"Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial","volume":"11","author":"Albain","year":"2010","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.annonc.2026.04.007_bib36","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1200\/JCO.2015.60.8133","article-title":"Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial","volume":"33","author":"Metzger Filho","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.04.007_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103097","article-title":"109O Adjuvant endocrine therapy for premenopausal invasive lobular carcinoma (ILC): results from SOFT and TEXT phase III studies","volume":"9","author":"Metzger","year":"2024","journal-title":"ESMO Open"},{"issue":"4_Supplement","key":"10.1016\/j.annonc.2026.04.007_bib38","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS21-PD14-08","article-title":"Abstract PD14-08: effectiveness of aromatase inhibitors versus tamoxifen in lobular compared to ductal carcinoma: Individual patient data meta-analysis of 9328 women with central histopathology, and 7654 women with e-cadherin status","volume":"82","author":"Hills","year":"2022","journal-title":"Cancer Res"},{"issue":"19","key":"10.1016\/j.annonc.2026.04.007_bib39","doi-asserted-by":"crossref","DOI":"10.1172\/JCI177813","article-title":"A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and nonresponders","volume":"135","author":"Zhang","year":"2025","journal-title":"J Clin Invest"},{"issue":"24","key":"10.1016\/j.annonc.2026.04.007_bib40","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1093\/jnci\/djt306","article-title":"An international Ki67 reproducibility study","volume":"105","author":"Polley","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.annonc.2026.04.007_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037379","article-title":"How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists","volume":"7","author":"Varga","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.annonc.2026.04.007_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103109","article-title":"121P endocrine response assessment in HR+ HER2- early breast cancer: concordance of central versus local Ki67 measurements in the ADAPTcycle trial","volume":"9","author":"Hamann","year":"2024","journal-title":"ESMO Open"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426001468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426001468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:45:39Z","timestamp":1782315939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753426001468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0923753426001468"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.04.007","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+\/HER2\u2212 and ADAPTcycle trials (N = 7914)","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}